Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Change in Receivables (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Change in Receivables for 6 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 160.81% to -$2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.4 million through Dec 2025, down 320.79% year-over-year, with the annual reading at -$4.4 million for FY2025, 320.79% down from the prior year.
  • Change in Receivables hit -$2.3 million in Q4 2025 for Rapid Micro Biosystems, down from -$618000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.8 million in Q4 2024 to a low of -$3.0 million in Q1 2025.
  • Historically, Change in Receivables has averaged -$92800.0 across 5 years, with a median of $44500.0 in 2021.
  • Biggest five-year swings in Change in Receivables: soared 71100.0% in 2022 and later plummeted 878.41% in 2023.
  • Year by year, Change in Receivables stood at -$1000.0 in 2021, then skyrocketed by 71100.0% to $710000.0 in 2022, then skyrocketed by 128.87% to $1.6 million in 2023, then soared by 132.55% to $3.8 million in 2024, then plummeted by 160.81% to -$2.3 million in 2025.
  • Business Quant data shows Change in Receivables for RPID at -$2.3 million in Q4 2025, -$618000.0 in Q3 2025, and $1.5 million in Q2 2025.